Floatz logo

mk-2206

Stage III Renal Cell Cancer AJCC v7

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Stage III Renal Cell Cancer AJCC v7 cohort.

Asset / SponsorPhaseRating
Sitravatinib
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

mk-2206 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →